Low Body Weight in Females Is a Risk Factor for Increased Tenofovir Exposure and Drug-Related Adverse Events
暂无分享,去创建一个
E. Clementi | D. Cattaneo | A. Riva | M. Galli | G. Rizzardini | C. Gervasoni | S. Baldelli | S. Landonio | P. Meraviglia | Serena Fucile | Laura Castagnoli
[1] C. Solas,et al. Renal Impairment in Patients Receiving a Tenofovir-cART Regimen: Impact of Tenofovir Trough Concentration , 2013, Journal of acquired immune deficiency syndromes.
[2] H. Trottier,et al. Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] G. di Perri,et al. Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-Sectional Study of HIV-Positive Patients with Normal Renal Function , 2013, Antimicrobial Agents and Chemotherapy.
[4] U. Bredeek,et al. SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] D. Francisci,et al. Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort. , 2013, The Journal of antimicrobial chemotherapy.
[6] S. Emery,et al. Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine , 2012, PloS one.
[7] M. Shlipak,et al. Association of tenofovir exposure with kidney disease risk in HIV infection , 2012, AIDS.
[8] M. Tolstrup,et al. Comparison of Bone and Renal Effects In HIV-infected Adults Switching to Abacavir or Tenofovir Based Therapy in a Randomized Trial , 2012, PloS one.
[9] R. Weber,et al. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir , 2012, AIDS.
[10] H. Yazaki,et al. Renal Function Declines More in Tenofovir- than Abacavir-Based Antiretroviral Therapy in Low-Body Weight Treatment-Naïve Patients with HIV Infection , 2012, PloS one.
[11] C. Okwundu,et al. WITHDRAWN. Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV. , 2012, The Cochrane database of systematic reviews.
[12] H. Yazaki,et al. Impact of Small Body Weight on Tenofovir-Associated Renal Dysfunction in HIV-Infected Patients: A Retrospective Cohort Study of Japanese Patients , 2011, PloS one.
[13] W. Johnson,et al. Renal dysfunction among HIV-infected patients starting antiretroviral therapy , 2011, AIDS.
[14] M. Sormani,et al. Risk factors for chronic kidney disease among human immunodeficiency virus-infected patients: A European case control study. , 2011, Clinical nephrology.
[15] B. Hendry,et al. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[16] D. Podzamczer,et al. Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1–Infected Adults: 48-Week Results From the ASSERT Study , 2010, Journal of acquired immune deficiency syndromes.
[17] D. Neau,et al. Prevalence and factors associated with renal impairment in HIV‐infected patients, ANRS C03 Aquitaine Cohort, France , 2010, HIV medicine.
[18] V. Soriano,et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations , 2010, AIDS.
[19] H. Mellor,et al. Gender differences in drug toxicity. , 2010, Trends in pharmacological sciences.
[20] A. Copas,et al. Tenofovir‐associated renal and bone toxicity , 2009, HIV medicine.
[21] J. Guitton,et al. Population Pharmacokinetics of Tenofovir in AIDS Patients , 2008, Journal of clinical pharmacology.
[22] L. Palmisano,et al. Gender differences in the treatment of HIV infection. , 2008, Pharmacological research.
[23] G. di Perri,et al. A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients. , 2008, Journal of chromatographic science.
[24] S. Urien,et al. Population Pharmacokinetics of Tenofovir in Human Immunodeficiency Virus-Infected Patients Taking Highly Active Antiretroviral Therapy , 2008, Antimicrobial Agents and Chemotherapy.
[25] D. Harris,et al. Pharmacokinetics of Antiretroviral Regimens Containing Tenofovir Disoproxil Fumarate and Atazanavir-Ritonavir in Adolescents and Young Adults with Human Immunodeficiency Virus Infection , 2007, Antimicrobial Agents and Chemotherapy.
[26] S. Urien,et al. Population Pharmacokinetics of Tenofovir in Human Immunodeficiency Virus-Infected Patients Taking Highly Active Antiretroviral Therapy , 2005, Antimicrobial Agents and Chemotherapy.